

## ASX Announcement



### First Commercial Sales of Remplir™ in Hong Kong as Asian Growth Gathers Momentum

***Remplir now selling in Australia, New Zealand, Singapore, the US and Hong Kong, with Canada and Thailand to follow***

- First commercial sales of Remplir™ achieved in Hong Kong, marking a key milestone in Orthocell's Asian growth strategy.
- Orthocell continues to execute its global commercialisation strategy, with Remplir now selling in Australia, New Zealand, Singapore, the US and Hong Kong, with first sales expected in Canada and Thailand in the near term.
- First sales follow the successful introduction of Remplir in Hong Kong, including the first surgical case and launch at the Hong Kong Orthopaedic Association (HKOA) 45th Annual Congress.
- Recently appointed internal Asia Pacific Commercial Director to commence in-market activities in Q1 CY26, working alongside highly credentialed in-country distributor MontsMed to drive sales growth.
- Hong Kong represents a significant growth opportunity, serving as a strategic entry point into the Guangdong–Hong Kong–Macao Greater Bay Area (GBA)—a region encompassing nine major cities and a population of approximately 100 million people.
- In partnership with MontsMed, Orthocell is well-positioned to drive market penetration through leading hospitals and specialist surgeons in Hong Kong.
- With over ~A\$50 million in cash and no debt, Orthocell remains well funded to continue expanding its global footprint and delivering on its commercialisation objectives.

**Perth, Australia; 10 December 2025:** Orthocell is pleased to announce the first commercial sales of Remplir™ in Hong Kong, representing a key milestone in the Company's Asian growth strategy. These initial sales follow the successful introduction of Remplir in Hong Kong, including its first surgical use and strong reception at the Hong Kong Orthopaedic Association (HKOA) 45th Annual Congress. The first sales to MontsMed provide immediate in-market availability and are expected to support multiple downstream sales as surgeons adopt the technology.

**Orthocell CEO and MD, Paul Anderson said** "First Hong Kong sales represent an important commercial milestone for Orthocell and a strong validation of Remplir's clinical value. We are well positioned to support MontsMed in driving adoption across leading hospitals in Hong Kong and the Greater Bay Area. We are executing our commercialisation strategy with discipline, and today's achievement marks another step forward in establishing Remplir as a new standard of care in peripheral nerve repair."

Orthocell's Chief Scientific Officer, Professor Zheng is currently in Hong Kong conducting onboarding and training sessions with MontsMed, with a focus on strengthening the scientific narrative and communicating the critical role of Remplir™ in high-quality peripheral nerve repair. These sessions support MontsMed's early commercial activities and help equip clinical and sales teams to drive surgeon engagement.

Hong Kong represents a significant growth opportunity for Orthocell, serving as a strategic entry point into the Guangdong–Hong Kong–Macao Greater Bay Area (GBA), a rapidly developing healthcare market of approximately 100 million people. Together with MontsMed, Orthocell is strongly positioned to drive market penetration through leading hospitals and specialist surgeons across the region.

To further accelerate commercial traction, Orthocell's recently appointed Asia Pacific Commercial Director will be active in market from Q1 CY26. Working closely with MontsMed, the Commercial Director will support awareness-building initiatives, surgeon education, and the expansion of Remplir sales across Hong Kong, with broader responsibilities across Australia and Asia.

#### **Momentum building across global markets**

Orthocell continues to execute its global commercialisation strategy, with Remplir having commenced sales in Singapore, the USA and now Hong Kong over the past 12 months, and additional sales expected in Canada and Thailand in the near term, supported by local distributor partnerships.

With ~A\$50 million in cash and no debt, Orthocell remains strongly funded and well-positioned to drive rapid product adoption and deliver a step change in revenue in FY26.

Remplir rollout in the US\$1.6 billion<sup>1</sup> US market also continues to build momentum, with in-country representatives working closely with distributors to gain hospital approvals, onboard surgeons, and establish active accounts. Initial US surgical case numbers continue to build.

#### **Release authorised by:**

**Paul Anderson**

**Orthocell Ltd CEO and MD**

---

<sup>1</sup> Nerve repair market sizes estimated using referenced papers from both US and OUS databases and studies.

## For more information, please contact:

### General enquiries

**Paul Anderson**

Orthocell Limited  
CEO and MD

P: +61 8 9360 2888

E: [paul.anderson@orthocell.com](mailto:paul.anderson@orthocell.com)

### Media enquiries

**Haley Chartres**

H<sup>^</sup>CK Director

P: +61 423 139 163

E: [haley@hck.digital](mailto:haley@hck.digital)

### Investor enquiries

**Shaun Duffy**

VECTOR Advisors

P: +61 404 094 384

E: [sduffy@vectoradvisors.au](mailto:sduffy@vectoradvisors.au)

## About Orthocell Limited

ACN 118 897 135

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed a network of specialist US distributors and recorded initial sales. The Company's flagship nerve repair product is also approved in Australia, New Zealand and Singapore where it is distributed by Device Technologies Group. Other Remplir approvals include Thailand, Canada and Hong Kong. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit [www.orthocell.com](http://www.orthocell.com) or follow us on Twitter @OrthocellLtd and LinkedIn [www.linkedin.com/company/orthocell-ltd](http://www.linkedin.com/company/orthocell-ltd)

## Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.